Evogene Ltd. beat EPS estimates 38% of the time across 16 reported quarters (6 beats, 10 misses), averaging -16.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.13 | not reported | not reported | |
| Q1 FY26 | $-0.27 | $-0.60 | -122.2% | Miss | |
| Q4 FY25 | not reported | $-0.61 | not reported | not reported | |
| Q3 FY25 | not reported | $-0.31 | not reported | not reported | |
| Q2 FY25 | not reported | $-0.62 | not reported | not reported | |
| Q1 FY25 | not reported | $-0.38 | not reported | not reported | |
| Q4 FY24 | not reported | $0.06 | not reported | not reported | |
| Q3 FY24 | not reported | $-1.31 | not reported | not reported | |
| Q2 FY24 | not reported | $-1.06 | not reported | not reported | |
| Q1 FY24 | not reported | $-0.08 | not reported | not reported | |
| Q4 FY23 | $-0.14 | $-0.13 | +7.1% | Beat | |
| Q3 FY23 | $-0.17 | $-0.08 | +52.9% | Beat |
Back to EVGN overview · EVGN holders · EVGN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.